ASCO® 2026 Highlights: Presenter Vignette – Tony Mok
Tony Mok
MD, FRCPC, FASCO
Chinese University of Hong Kong
8502
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
This program has been made possible through unrestricted support from